Elezanumab

TargetMol
Product Code: TAR-T76863
Product Group: Primary Antibodies
Supplier: TargetMol
CodeSizePrice
TAR-T76863-1mg1mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T76863-5mg5mg£677.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T76863-10mg10mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T76863-25mg25mg£1,500.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T76863-50mg50mg£1,990.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T76863-100mg100mg£2,681.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Antibody Clonality: Monoclonal
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM.Elezanumab promotes neuroregeneration, neuroprotection, and neural restoration in models of neuronal injury and demyelination. Elezanumab promotes the growth of corticospinal axons into spinal gray matter and enhances serotonergic innervation in the ventral horn, forming synaptic connections in the caudal part of cervical lesions.
CAS:
1791416-49-3
Pathway:
Stem Cells
Purity:
0.98
Target:
TGF-beta/Smad

References

Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492. Peer B Jacobson, et al. Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. Neurobiol Dis. 2021 Jul;155:105385.